Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent
Provided by
Dow Jones
By Dominic Chopping
Danish pharmaceutical giant Novo Nordisk has agreed to buy three manufacturing sites for $11 billion as it continues to boost production capacity to satisfy surging demand for its weight-loss drugs.
Under the deal, Ozempic maker Novo Nordisk will buy the Catalent sites from Novo Holdings, which has agreed to take over the U.S. drugmaker.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
February 05, 2024 06:38 ET (11:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States